Codon-optimized non-glycosylated Aet coding gene as well as recombinant and application of codon-optimized non-glycosylated Aet coding gene
By expressing the optimized non-glycosylated Aet gene in yeast intracellularly, using endogenous signal peptides to remove glycosylation pathways, the problem of low catalytic activity of yeast is solved, efficient Ala-Gln synthesis is achieved, and industrial production needs are met And ensure product safety.
Patent Information
- Application Number
- CN202411293883.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2022-07-06
- Publication Date
- 2024-11-08
AI Technical Summary
In the prior art, recombinant yeast has low catalytic activity during the synthesis of Ala-Gln, resulting in a long reaction time and low substrate conversion rate, making it difficult to meet the needs of industrial production. At the same time, bacterial endotoxins and toxic proteins remain in the process of recombinant E. coli. question.
The non-glycosylation-encoding Aet gene after codon optimization is expressed intracellularly in yeast, and the glycosylation pathway is removed using endogenous signal peptides to avoid deglycosylated enzyme treatment, improve the catalytic activity of Aet, and build high activity Recombinant yeast for efficient synthesis.
It significantly improves the catalytic activity of recombinant yeast, shortens the reaction time, improves the substrate conversion rate, reduces industrial costs, promotes the industrial production process of Ala-Gln, and ensures the biosafety of the product.
Smart Images

Figure BDA0005045364070000121 
Figure HDA0005045364090000011 
Figure HDA0005045364090000021
Abstract
Description
Technical Field
[0001] The invention belongs to the field of microbial genetic engineering applications, and specifically relates to a class of codon-optimized non-glycosylated Aet-encoding genes, recombinants thereof and applications. Background Art
[0002] The Escherichia coli expression system is the earliest prokaryotic expression system developed and applied. It has natural advantages such as clear genetic background (whole genome sequencing), short growth cycle (fast reproduction), simple transformation operation (mature gene molecular cloning technology), high protein expression level (accounting for 20-40% of total cell protein), low production cost, strong anti-pollution ability and easy high-density culture. It has been widely used in the heterologous expression of various proteins.
[0003] Aet can directly convert L-alanine methyl ester hydrochloride (L-AlaOMe) and L-glutamine (L-Gln) into Ala-Gln. With its advantages of cheap and readily available raw materials, few reaction steps, mild reaction conditions, low environmental pollution and few by-products, it has become a new method for synthesizing Ala-Gln and has the potential to be applied to industrial production. Patent CN201611254213.2 discloses a method for synthesizing Ala-Gln using heterologously expressed Aet recombinant Escherichia coli. The method can quickly complete the catalytic reaction within 10 minutes, with a substrate conversion rate of up to 83%, achieving efficient synthesis of Ala-Gln and laying a solid theoretical foundation for its industrial production process.
[0004] As an amino acid drug with therapeutic effects, the safety of Ala-Gln in the medical field is of vital importance. The national standard has clear provisions for each drug form of Ala-Gln, among which the requirement for Ala-Gln powder is: the bacterial endotoxin content per milligram should be less than 0.050EU; the requirement for Ala-Gln injection is: the amount of bacterial endotoxin per milliliter should be less than 0.50EU; the requirement for Ala-Gln for injection is: the amount of bacterial endotoxin per milliliter should be less than 0.050EU. However, the process of synthesizing Ala-Gln using recombinant Escherichia coli not only involves the use of antibiotics, toxic inducers (IPTG) and boric acid / borax, but also bacterial endotoxins and some toxic proteins may remain in the final product. Therefore, recombinant Escherichia coli-derived Ala-Gln products have certain biosafety risks, which increases the difficulty of their application in the medical field and limits their dual benefits in both treatment and economy.
[0005] The yeast expression system is another heterologous protein expression system that emerged after Escherichia coli. It not only has many genes, organelles and functions similar to those of higher eukaryotic organisms, but also has some advantages of prokaryotic expression systems (such as simple genetic manipulation, short production cycle, low production cost and easy cultivation, etc.), and has been successfully applied to the heterologous expression of many commercially valuable proteins. Among them, Saccharomyces cerevisiae is a safe organism (Generally Recognized as Safe, GRAS) certified by the US FDA; Pichia pastoris was also listed as a microorganism with safety qualification (Qualified Presumption of Safety, QPS) by the European Food Safety Authority (EFSA) in 2008 (Romanos MA et al. Yeast, 1992, 8 (6): 423-488.; Sundh I, Melin P. Antonie Van Leeuwenhoek, 2011, 99 (1): 113-119.). Using safer yeast as the chassis cell of the cell factory and using nutritional deficiency as a screening marker to construct recombinant yeast overexpressing Aet to synthesize Ala-Gln can effectively make up for the shortcomings of the E. coli expression system in terms of product safety. Patent ZL201611254240.X discloses a method for synthesizing Ala-Gln using recombinant brewer's yeast overexpressing Aet, the highest substrate conversion rate of which is about 60%, and the reaction time is 40min. Although the safety of the Ala-Gln product is guaranteed, the low catalytic activity of the recombinant brewer's yeast overexpressing Aet leads to the problems of long reaction time and low substrate conversion rate in the synthesis of Ala-Gln, making it difficult for the yeast expression system to meet the industrial production needs of Ala-Gln. Therefore, increasing the expression level and catalytic activity of Aet in recombinant yeast is the key to solving the bottleneck problem of efficient synthesis of Ala-Gln in the yeast expression system.
[0006] After being expressed in eukaryotic cells, genes of prokaryotic origin will be glycosylated according to the processing method in eukaryotic cells. Although the expressed protein can be treated with deglycosylation enzymes, this idea is not feasible in industry because it is time-consuming, labor-intensive, and uneconomical; in eukaryotic cells, glycosylation is a normal expression state of host cells and theoretically does not affect enzyme activity. However, if a site suitable for glycosylation in a eukaryotic cell mutates, it often leads to changes in the structure of the enzyme, and the function of the enzyme itself is lost / changed due to the site mutation. How to reasonably remove the glycosylation site while ensuring that the enzyme activity is not lost, or even significantly improve the enzyme activity, is a technical problem that technicians in this field urgently need to solve. Summary of the invention
[0007] In order to solve the above problems, the present invention designs a method for bypassing the secretory expression pathway by expressing Aet intracellularly and removing the endogenous signal peptide, thereby achieving in situ removal of glycosylation and improving the catalytic activity of amino acid ester acyl transferase (Aet) in recombinant yeast. This method avoids the high cost problem caused by treating glycosylated products with deglycosylation enzymes, reduces industrial costs, and is conducive to promoting the industrialization process.
[0008] One of the purposes of the present invention is to provide a class of codon-optimized non-glycosylated gene sequences encoding amino acid ester acyltransferase Aet, which are sequences in which nucleotide sequences that can cause glycosylation are removed / changed. The removal / change of nucleotide sequences that can cause glycosylation includes but is not limited to removal of secretory expression signal peptides, glycosylation site mutations, and deglycosylation enzyme treatment.
[0009] For the technical solution described above, it is further preferred that the glycosylation site includes but is not limited to the N-glycosylation site and its conserved sequence (NXS / T) listed in the present invention, such as N67-RT, N318-NS, N442-RT and N608-AT; and O-glycosylation site, such as T22, T119, S209, T427 and T444. Specifically, the glycosylation site is N442-RT and mutated to N442X; the embodiment of the present invention lists the glycosylation site mutation to N442S, N442A or N442E.
[0010] For the technical solution described above, it is further preferred that the class of non-glycosylated Aet encoding sequences after codon optimization has a nucleotide sequence as shown in SEQ ID NO.3, wherein SEQ ID NO.1 and SEQ ID NO.2 are sequences without the secretory expression signal peptide, and SEQ ID NO.3 is the mutated N442S.
[0011] The second object of the present invention is to provide a recombinant vector capable of achieving the intracellular expression of the non-glycosylated Aet gene encoded after codon optimization as described above.
[0012] For the technical solution described above, it is further preferred that the vector is a pPIC series vector or a pRS series vector; different vectors correspond to different host types, for example: pPIC3.5K and pPIC9K vectors correspond to Pichia pastoris, and pRS424 vector corresponds to Saccharomyces cerevisiae, but not limited thereto.
[0013] The third object of the present invention is to provide a highly active recombinant yeast capable of expressing the above-mentioned codon-optimized non-glycosylated Aet encoding sequence, namely, Aet recombinant yeast.
[0014] For the technical solution described above, it is further preferred that the recombinant yeast host is selected from any one of Saccharomyces cerevisiae, Pichia pastoris, Kluyveromyces lactis and Kluyveromyces marxianus.
[0015] For the technical solution described above, further preferably, the preparation method of the Aet recombinant yeast comprises one or a combination of the following methods:
[0016] (a) The intracellular expression of Aet was used to avoid the change of Aet structure and improve the catalytic activity of Aet;
[0017] (b) The glycosylation site was removed, avoiding the post-modification of Aet and improving the catalytic activity of Aet;
[0018] (c) The gene sequence without the endogenous signal peptide was used to avoid the change of Aet structure and improve the catalytic activity of Aet.
[0019] By using one or a combination of the above methods, Aet recombinant yeast was constructed as a whole-cell catalyst, which improved the catalytic activity of the recombinant yeast, shortened the reaction time, and achieved efficient synthesis of dipeptides.
[0020] The fourth object of the present invention is to provide a method for improving the catalytic activity of Aet recombinant yeast, namely, the use of Aet recombinant yeast in the efficient catalytic production of alanine dipeptide and L-alanyl-L-glutamine, comprising the following steps:
[0021] (a) dissolving the substrate in a solvent system containing recombinant yeast, wherein the solvent system may be any one of water, buffer or cell culture medium;
[0022] (b) controlling the reaction pH at 7.0-10.0 and maintaining the reaction temperature at 18-30° C. to carry out biosynthesis of the dipeptide;
[0023] For the technical solution described above, it is further preferred that the pH range is 7.0-9.0.
[0024] For the technical solution described above, it is further preferred that the substrate has a wide range of selectivity, including but not limited to alanine methyl ester hydrochloride, glutamine, alanine ethyl ester hydrochloride, etc.
[0025] For the technical solution described above, it is further preferred that the mass concentration of the substrate in the solvent system containing the recombinant yeast is 50-600mmol / L LaOMe and 50-600mmol / L Gln. Compared with the prior art, the present invention has the following beneficial effects:
[0026] The present invention solves the bottleneck problem existing in the prior art and achieves the goal of efficiently synthesizing alanylglutamine using recombinant yeast. After technical transformation, the specific production intensity is increased by up to 11 times at 100mM substrate and up to 10.2 times at 600mM substrate, which promotes its application in industrial production. While ensuring the biosafety of the product, the reaction time is greatly shortened, and the production efficiency and substrate conversion rate are improved. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 Bioinformatics prediction map of Aet amino acid sequence;
[0028] Figure 2 Comparison of catalytic activities of six Pichia pastoris strains;
[0029] Figure 3 Comparison of catalytic activities of three recombinant Saccharomyces cerevisiae strains;
[0030] Figure 4 It is the identification diagram of glycosylation in secretory expression of Aet in yeast;
[0031] Figure 5 The effect of N-glycosylation modification site mutation on the catalytic activity of recombinant Saccharomyces cerevisiae. DETAILED DESCRIPTION
[0032] The specific implementation modes of the present invention are described in detail below in conjunction with the accompanying drawings, but it should be understood that the protection scope of the present invention is not limited by the specific implementation modes.
[0033] In the present invention, unless otherwise specified, percentages and percentage contents are all by mass. Unless otherwise specified, the experimental methods used are all conventional methods, and the materials and reagents used can be purchased from commercial sources.
[0034] Example 1
[0035] 1) Glycosylation site prediction
[0036] First, the Aet amino acid sequence was subjected to bioinformatics analysis. Based on the glycoprotein structure of higher eukaryotes, the glycosylation modification sites and endogenous signal peptides of Aet were predicted using NetNGlyc 1.0Server (http: / / www.cbs.dtu.dk / services / NetNGlyc / ), NetOGlyc4.0Server (http: / / www.cbs.dtu.dk / services / NetOGlyc / ), NetCGlyc 1.0Server (http: / / www.cbs.dtu.dk / services / NetCGlyc / ) and SignalP-5.0Server (http: / / www.cbs.dtu.dk / services / SignalP / ). Then, the transmembrane helix of Aet was predicted using TMHMM Server v.2.0 (http: / / www.cbs.dtu.dk / services / TMHMM / ) to exclude the situation where the transmembrane sequence region was incorrectly predicted to be glycosylated. The results are shown in Figure 1. Figure 1 As shown in A / B, four potential N-glycosylation modification sites (N67-RT, N318-NS, N442-RT and N608-AT) and five O-glycosylation modification sites (T22, T119, S209, T427 and T444) were found, and no C-glycosylation modification sites were found. Figure 1 As shown in C / D, there is a 97.6% probability that the first 20 amino acids are endogenous signal peptides, and there are no transmembrane proteins that interfere with the accuracy of glycosylation prediction.
[0037] 2) Codon optimization and cloning of Aet gene sequence
[0038] The amino acid ester acyltransferase Aet described in the present invention is derived from a strain of Sphingobacterium siyangensis SY1 (see patent ZL201611254240.X). In order to increase the expression level of Aet in a heterologous host, its sequence is optimized to be AET suitable for the P. pastoris host. P Genes and AETs suitable for S. cerevisiae hosts S When the Codon Adaptation Index (CAI) is within the range of 0.8-1.0 and the GC content is controlled at 30-40%, the target gene will obtain good transcription and translation efficiency in the heterologous host, thereby increasing the expression of the target protein.
[0039] AET PThe gene fragment was used as a template and the upstream primer AET was used P1800 -F and downstream primer AET P1800 -R, AET without endogenous signal peptide obtained by polymerase chain reaction (PCR) cloning P1800 The gene, the product contains 1803 nucleotides, the nucleotide sequence is shown in SEQ ID No.1, encoding 600 amino acids.
[0040] AET S The gene fragment was used as a template and the upstream primer AET was used S1800 -F and downstream primer AET S1800 -R, AET without endogenous signal peptide obtained by PCR cloning S1800 The gene, the product contains 1803 nucleotides, the nucleotide sequence is shown in SEQ ID No. 2, encoding 600 amino acids.
[0041] 3) Construction of extracellular expression recombinant yeast
[0042] The target gene of the present invention can be used to construct Pichia pastoris intracellular expression and extracellular expression vectors, and the specific steps are as follows:
[0043] (1) Construction of recombinant Pichia pastoris expressing Aet extracellularly with endogenous signal peptide
[0044] The multi-copy plasmid pPIC9K and the target gene AET were cleaved using restriction endonucleases EcoRI and Not I. P Perform double enzyme digestion; ligate after purification and transfer into E.coli DH5α. The verified recombinant plasmid is named pPIC9K-AET P The recombinant plasmid was linearized using SacI and transformed into P. pastoris by electroporation. + The recombinant Pichia yeast expressing Aet with endogenous signal peptide and phenotype and tolerant to 4.0 mg / mL G418 final concentration was named KP 9K A P .
[0045] (2) Construction of recombinant Pichia pastoris expressing Aet extracellularly without endogenous signal peptide
[0046] The multi-copy plasmid pPIC9K and the target gene AET were cleaved using restriction endonucleases EcoRI and Not I. P1800 Perform double enzyme digestion; ligate after purification and transfer into E.coli DH5α. The verified recombinant plasmid is named pPIC9K-AET P1800 The recombinant plasmid was linearized using Sac I and transformed into P. pastoris by electroporation.+ The recombinant Pichia yeast expressing Aet without endogenous signal peptide and withstanding the final concentration of 4.0 mg / mL G418 was named KP 9K A P1800 .
[0047] (3) Construction of recombinant Pichia pastoris expressing Aet extracellularly with glycosylation site mutation
[0048] According to the glycosylation prediction results, one of the sites with the potential for N-glycosylation modification (aspartic acid residue at position 442 / N) was randomly mutated. P Plasmid was used as template, and 19 pairs of primers for site-directed mutation at position 442 were designed to construct the recombinant vector. However, only one pair of primers had an obvious effect, and they were used to construct the recombinant vector. The constructed new vector was named pPIC9K-AET. P -N442X, (where X represents the abbreviation of the amino acid after mutation); wherein the sequence information of this pair of primers is as follows:
[0049] SEQ ID NO.4: N442S-f5'-actcccgtgttcggctttgaattaacccaccttg-3';
[0050] SEQ ID NO.5: N442S-r5'-caaggtgggttaattcaaagccgaacacggggagt-3';
[0051] The recombinant plasmid was linearized with Sac I and transformed into Saccharomyces cerevisiae EBY100 by electroporation. + The recombinant Pichia yeast expressing Aet with endogenous signal peptide and phenotype and tolerant to 4.0 mg / mL G418 final concentration was named KP 9K A P N442S, the nucleotide sequence of the N442S mutant is shown in SEQ ID NO.5.
[0052] 4) Construction of recombinant Pichia pastoris expressing Aet
[0053] The target gene of the present invention can be used to construct an intracellular expression vector of Pichia pastoris and an intracellular expression vector of Saccharomyces cerevisiae, and the specific steps are as follows:
[0054] (1) Construction of recombinant Pichia pastoris expressing Aet intracellularly with endogenous signal peptide
[0055] The multi-copy plasmid pPIC3.5K and the target gene AET were cleaved using restriction endonucleases EcoRI and Not I. PPerform double enzyme digestion; ligate after purification and transfer into E.coli DH5α. The verified recombinant plasmid is named pPIC3.5K-AET P The recombinant plasmid was linearized using Sac I and transformed into P. pastoris by electroporation. + The recombinant Pichia yeast expressing Aet intracellularly with endogenous signal peptide was named KP. 3.5K A P .
[0056] (2) Construction of recombinant Pichia pastoris expressing Aet intracellularly without endogenous signal peptide
[0057] The multi-copy plasmid pPIC3.5K and the target gene AET were cleaved using restriction endonucleases EcoRI and Not I. P1800 Perform double enzyme digestion; ligate after purification and transfer into E.coli DH5α. The verified recombinant plasmid is named pPIC3.5K-AET P1800 The recombinant plasmid was linearized using Sac I and transformed into P. pastoris by electroporation. + The recombinant Pichia yeast expressing Aet intracellularly without endogenous signal peptide was named KP. 3.5K A P1800 .KP 3.5K A P1800 The invention relates to the recombinant Pichia pastoris capable of increasing the expression amount and catalytic activity of Aet.
[0058] 5) Construction of recombinant Saccharomyces cerevisiae expressing Aet intracellularly
[0059] The previously authorized patent (ZL201611254240.X) constructed a recombinant brewer's yeast expressing Aet extracellularly, which can be used as a control strain in the embodiments / application examples / comparative examples of the present invention.
[0060] The target gene of the present invention can be used to construct an intracellular expression vector of Saccharomyces cerevisiae, and the specific steps are as follows:
[0061] (1) Construction of recombinant Saccharomyces cerevisiae expressing Aet intracellularly with endogenous signal peptide
[0062] The multi-copy plasmid pRS424 and the target gene AET were cleaved using restriction endonucleases Sac I and Xho I. S Perform double enzyme digestion; ligate after purification and transfer into E.coli DH5α. The verified recombinant plasmid is named pRS424-AET SThe recombinant plasmid was transferred into S.cerevisiae to construct a recombinant Saccharomyces cerevisiae expressing Aet in the cell containing the endogenous signal peptide, named EP 424 A S .
[0063] (2) Construction of recombinant Pichia pastoris expressing Aet intracellularly without endogenous signal peptide
[0064] The multi-copy plasmid pRS424 and the target gene AET were cleaved using restriction endonucleases Sac I and Xho I. S1800 Perform double enzyme digestion; ligate after purification and transfer into E.coli DH5α. The verified recombinant plasmid is named pRS424-AET S1800 The recombinant plasmid was transferred into S.cerevisiae to construct a recombinant Saccharomyces cerevisiae expressing Aet in the cell without endogenous signal peptide, named EP 424 A S1800 EP 424 A S1800 The invention relates to the recombinant Saccharomyces cerevisiae capable of increasing the expression amount and catalytic activity of Aet.
[0065] 6) Construction of recombinant Saccharomyces cerevisiae expressing Aet extracellularly with glycosylation site mutation
[0066] Intracellular expression is a method of increasing the expression amount and catalytic activity of Aet in recombinant yeast according to the present invention. On this basis, the present invention also provides a method for eliminating the negative impact of glycosylation on Aet enzyme activity.
[0067] Taking Saccharomyces cerevisiae as an example, based on the glycosylation prediction results, one of the sites with the potential for N-glycosylation modification (the 442nd aspartic acid residue / N) was subjected to site-directed saturation mutagenesis. s The extracellular expression vector was used as a template, and 19 pairs of primers for site-directed mutation at position 442 were designed to construct a recombinant vector, which was then transformed into Saccharomyces cerevisiae EBY100. Based on the culture conditions and induction conditions of the recombinant Saccharomyces cerevisiae described in the present invention, and the reaction conditions for catalytic synthesis of dipeptides using the whole cell of the recombinant yeast, the catalytic activities of the 19 mutants were compared under the same conditions, among which the unmutated recombinant Saccharomyces cerevisiae (ZL201611254240.X) was used as a control strain and named N442N.
[0068] There are three mutants with obvious effects. Therefore, the extracellular recombinant Saccharomyces cerevisiae capable of eliminating the negative effects of glycosylation on Aet enzyme activity according to the present invention are S.cerevisiae N442S, N442A and N442E in order of beneficial effects (the nucleotide sequence of the best N442S mutant is shown in SEQ ID NO.3), and the corresponding primer sequence information is as follows:
[0069] SEQ ID NO.4: N442S-f5'-actcccgtgttcggctttgaattaacccaccttg-3';
[0070] SEQ ID NO.5: N442S-r5'-caaggtgggttaattcaaagccgaacacggggagt-3';
[0071] SEQ ID NO.6: N442A-f5'-actcccgtgttcgcgcttgaattaacccacc-3″;
[0072] SEQ ID NO.7: N442A-r5'-ggtgggttaattcaagcgcgaacacgggagt-3;
[0073] SEQ ID NO.8: N442E-f5'-actcccgtgttcgttcttgaattaacccacc-3;
[0074] SEQ ID NO.9: N442E-r5'-ggtgggttaattcaagaacgaacacgggagt-3';
[0075] 7) Functional analysis and verification
[0076] The culture conditions and induction conditions of the recombinant yeast of the present invention, as well as the reaction conditions for catalyzing the synthesis of dipeptides using the recombinant yeast are as follows:
[0077] (1) Culture and induction conditions of recombinant Pichia pastoris
[0078] Two KP strains expressing Aet extracellularly 9K A P and KP 9K A P1800 Pichia pastoris KP containing the empty plasmid pPIC9K 9K The negative control strains; the two KP strains expressing Aet intracellularly 3.5K A P and KP 3.5K A P1800 Pichia pastoris KP containing the empty plasmid pPIC3.5K 3.5K is the negative control strain; KP 9K A P / KP 3.5K A P , KP 9K A P1800 / KP 3.5KA P1800 and KP 9K A P N442X were used as control strains. The activated recombinant Pichia was inoculated into 25 mL BMGY seed medium at an inoculum of 1-10% (v / v), and cultured at 20-30°C, 150-250 rpm for 12-24 h; the cells were collected by centrifugation, transferred to 50-100 mL BMMY induction medium, cultured at 20-30°C, 150-250 rpm, and supplemented with 1-3% (v / v) methanol every 24 h for 2-5 d of induction.
[0079] The BMGY seed culture medium (g / L): 10% yeast extract powder, 20% peptone, add 700mL ultrapure water, sterilize at 121°C for 20min; when the temperature is cooled to about 60°C, add 100mL 10×YNB solution, 100mL 1mol / L potassium phosphate buffer, 100mL 10×GY solution and 2mL 500×B solution; the BMMY induction culture medium is obtained by replacing the 10×GY solution in the BMGY seed culture medium with 10×M. Among them, 10×YNB solution: weigh 134g YNB powder and dissolve it in 1000mL ultrapure water, sterilize at 121℃ for 15min, and store at 4℃; 500×B solution: weigh 20mg biotin and dissolve it in 100mL ultrapure water, sterilize by membrane, and store at 4℃; 10×M solution: measure 5mL methanol, add it to 95mL ultrapure water, sterilize by membrane, and store at 4℃; 10×GY solution: measure 100mL glycerol, add it to 900mL ultrapure water, sterilize at 121℃ for 15min, and store at room temperature; 1mol / L potassium phosphate buffer: weigh 3.012g K2HPO4 and 11.813g KH2PO4 and dissolve them in 100mL ultrapure water, sterilize at 121℃ for 15min, and store at room temperature.
[0080] (2) Culture and induction conditions of recombinant Saccharomyces cerevisiae overexpressing Aet
[0081] Two EP strains expressing Aet intracellularly 424 A S and EP 424 A S1800 The Saccharomyces cerevisiae EP containing the empty plasmid pRS424 424As negative control strain; 19 N442 series mutants expressing Aet extracellularly, and the recombinant Saccharomyces cerevisiae expressing Aet extracellularly disclosed in patent ZL201611254240.X were used as comparison strains. The four recombinant Saccharomyces cerevisiae after activation were inoculated into 25mL SD / -Trp-Ura defective medium (containing 2% glucose) at an inoculation amount of 1-10% (v / v), and cultured at 20-30°C, 150-250rpm for 12-24h; the cells were collected by centrifugation, transferred to 50-100mL SG / -Trp-Ura defective medium (containing 2% galactose), and cultured at 20-30°C, 150-250rpm for 2-5d.
[0082] The seed culture medium is SD / -Trp-Ura defective culture medium (g / L): YNB 6.7, amino acid deficiency mixture (DO Supplement-Leu / -Trp / -Ura) 0.6, add 880mL deionized water, sterilize at 121℃ for 20min; when the temperature is cooled to about 60℃, add 100mL 20% glucose solution, 10mL 10×Thr solution and 10mL 10×Leu solution; the induction culture medium is SG-Trp-Ura defective culture medium, which uses galactose to replace the glucose in SD / -Trp-Ura defective culture medium. Among them, 10×Thr solution: weigh 2g Thr powder, dilute to 100mL with deionized water, mix well, sterilize by membrane, and store at room temperature; 10×Leu solution: weigh 0.6g Leu powder, dilute to 100mL with deionized water, sterilize at 121℃ for 20min, and store at room temperature.
[0083] (3) Reaction conditions for the synthesis of glutathione catalyzed by recombinant yeast
[0084] The recombinant yeast of the present invention can be used to carry out the biosynthesis of dipeptides according to the methods in the prior art, and its substrate can be described as a substrate including a carboxyl component and an amine component according to the prior art. The carboxyl component is selected from amino acid amides and amino acid esters; the amine component is selected from amino acids and amino acid amides. Taking the biosynthesis of Ala-Gln as a more specific example, the reaction conditions for the recombinant yeast catalytic synthesis of Ala-Gln of the present invention are: adding the recombinant yeast (or cell culture fluid) to a buffer containing 100mmol / L AlaOMe and 200mmol / L Gln, so that the amount of bacteria in the reaction solution is maintained at OD 600=0.5-5.0; adjust the reaction pH in the range of 7.0-10.0 with alkali solution, control the reaction temperature at 18-30°C, and carry out the biosynthesis of Ala-Gln; take samples at different time points, collect the samples by centrifugation, and detect the synthesis amount of Ala-Gln by HPLC after heating and inactivation. The catalytic activity of different strains is characterized by comparing the reaction endpoint and the maximum substrate conversion rate. Theoretically, there is no upper and lower limit for the substrate concentration in the reaction system, but the substrate concentration is limited to a certain extent by the solubility of the substrate. In the present invention, the concentration of the carboxyl component and the amine component in the initial reaction system can be set to 50-600mmol / L. Unless otherwise specified, except for replacing the corresponding substrate, the above-mentioned reaction conditions are used for the biosynthesis of other dipeptides.
[0085] Application Example 1 Extracellular expression of Aet recombinant Pichia pastoris KP containing endogenous signal peptide 9K A P Synthesis of Ala-Gln
[0086] Weigh 1.40 g of AlaOMe (100 mmol / L) and 2.92 g of Gln (200 mmol / L) and dissolve them in 100 mL of KP 9K A P In the cell culture medium, the reaction temperature was controlled at 28°C, and the reaction pH was maintained constant at 8.5 with 6 mmol / L NaOH solution. Samples were taken every 5 minutes during the reaction. When the reaction reached the end point, the cells were removed by centrifugation and the reaction was terminated by heating. The results of high performance liquid chromatography (Appendix VD of Part II of the Chinese Pharmacopoeia 2010 Edition) showed that at 20 minutes, the maximum amount of Ala-Gln synthesis was 1.27 g, and the substrate conversion rate was 59%.
[0087] Application Example 2: Extracellular Expression of Aet Recombinant Pichia pastoris KP without Endogenous Signal Peptide 9K A P1800 Synthesis of Ala-Gln
[0088] Weigh 1.40 g of AlaOMe (100 mmol / L) and 2.92 g of Gln (200 mmol / L) and dissolve them in 100 mL of KP 9K A P1800 In the cell culture medium, the reaction temperature was controlled at 28°C, and the reaction pH was maintained constant at 8.5 with 6 mmol / L NaOH solution. Samples were taken every 5 minutes during the reaction. When the reaction reached the end point, the cells were removed by centrifugation and the reaction was terminated by heating. The results of high performance liquid chromatography (Appendix VD of Part II of the Chinese Pharmacopoeia 2010 Edition) showed that at 20 minutes, the maximum amount of Ala-Gln synthesis was 1.23 g, and the substrate conversion rate was 57%.
[0089] Application Example 3: Intracellular expression of Aet recombinant Pichia pastoris KP containing endogenous signal peptide3.5K A P Synthesis of Ala-Gln
[0090] Weigh 1.40 g of AlaOMe (100 mmol / L) and 2.92 g of Gln (200 mmol / L) and dissolve them in 100 mL of KP 3.5K A P In the cell culture medium, the reaction temperature was controlled at 28°C, and the reaction pH was maintained at 8.5 with 6 mmol / L NaOH solution. Samples were taken every 5 minutes during the reaction. When the reaction reached the end point, the cells were removed by centrifugation and the reaction was terminated by heating. The results of high performance liquid chromatography (Appendix VD of Part II of the Chinese Pharmacopoeia 2010 Edition) showed that at 5 minutes, the maximum amount of Ala-Gln synthesis was 1.58 g, and the substrate conversion rate was 73%.
[0091] Application Example 4 Intracellular Expression of Aet Recombinant Pichia pastoris KP without Endogenous Signal Peptide 3.5K A P1800 Synthesis of Ala-Gln
[0092] Weigh 1.40 g of AlaOMe (100 mmol / L) and 2.92 g of Gln (200 mmol / L) and dissolve them in 100 mL of KP 3.5K A P1800 In the cell culture medium, the reaction temperature was controlled at 28°C, and the reaction pH was maintained at 8.5 with 6 mmol / L NaOH solution. Samples were taken every 5 minutes during the reaction. When the reaction reached the end point, the cells were removed by centrifugation and the reaction was terminated by heating. The results of high performance liquid chromatography (Appendix VD of Part II of the Chinese Pharmacopoeia 2010 Edition) showed that at 5 minutes, the maximum amount of Ala-Gln synthesis was 1.73 g, and the substrate conversion rate was 80%.
[0093] Application Example 5 Synthesis of Ala-Gln by Recombinant Pichia pastoris with Mutation of Glycosylation Sites
[0094] Weigh 1.40 g of AlaOMe (100 mmol / L) and 2.92 g of Gln (200 mmol / L) and dissolve them in 100 mL of KP 9K A P In the N442S cell culture medium, the reaction temperature was controlled at 28°C, and the reaction pH was maintained at 8.5 with 6mmol / L NaOH solution. Samples were taken every 5 minutes during the reaction. When the reaction reached the end point, the cells were removed by centrifugation and the reaction was terminated by heating. The detection was performed using high performance liquid chromatography (Appendix VD of Part II of the 2010 edition of the Chinese Pharmacopoeia), with the unmutated recombinant Saccharomyces cerevisiae (ZL201611254240.X) as a control strain. The results are as follows: Figure 5When the N at position 442 was mutated to A, S and E residues, the amount of Ala-Gln synthesized was 1.60g, 1.77g and 1.55g at 5min, and the substrate conversion rate was 75.2%, 81.4% and 71.3% respectively; when it was mutated to P residue, the recombinant yeast completely lost its catalytic activity.
[0095] Application Example 6: Intracellular expression of Aet recombinant Saccharomyces cerevisiae EP containing endogenous signal peptide 424 A S Synthesis of Ala-Gln
[0096] Weigh 1.40 g of AlaOMe (100 mmol / L) and 2.92 g of Gln (200 mmol / L), dissolve in 90 mL of buffer; add 10 mL of recombinant Saccharomyces cerevisiae EP 424 A S , the reaction temperature was controlled at 24°C, and the reaction pH was maintained at 8.0 with 6mmol / L NaOH solution. Samples were taken every 5 minutes during the reaction. When the reaction reached the end point, the cells were removed by centrifugation and the reaction was terminated by heating. The results of high performance liquid chromatography (Appendix VD of Part II of the Chinese Pharmacopoeia 2010 Edition) showed that at 5 minutes, the maximum amount of Ala-Gln synthesis was 1.40g, and the substrate conversion rate was 64.8%.
[0097] Application Example 7 Intracellular Expression of Aet Recombinant Saccharomyces cerevisiae EP without Endogenous Signal Peptide 424 A S1800 Synthesis of Ala-Gln
[0098] Weigh 1.40 g of AlaOMe (100 mmol / L) and 2.92 g of Gln (200 mmol / L), dissolve in 90 mL of buffer; add 10 mL of recombinant Saccharomyces cerevisiae EP 424 A S1800 , the reaction temperature was controlled at 24°C, and the reaction pH was maintained at 8.0 with 6mmol / L NaOH solution. Samples were taken every 5 minutes during the reaction. When the reaction reached the end point, the cells were removed by centrifugation and the reaction was terminated by heating. The results of high performance liquid chromatography (Appendix VD of Part II of the Chinese Pharmacopoeia 2010 Edition) showed that at 5 minutes, the maximum amount of Ala-Gln synthesis was 1.65g, and the substrate conversion rate was 76%.
[0099] Application Example 8 Synthesis of Ala-Gln by Recombinant Saccharomyces cerevisiae Using Mutation of Glycosylation Sites
[0100] Weigh 1.40g of AlaOMe (100mmol / L) and 2.92g of Gln (200mmol / L), dissolve in 100mL S.cerevisiae N442S cell culture medium, control the reaction temperature to 24°C, use 6mmol / L NaOH solution to maintain the reaction pH constant at 8.5, and sample once every 5 minutes during the reaction. When the reaction reaches the end point, centrifuge to remove the cells and heat to terminate the reaction. Detection was performed using high performance liquid chromatography (Appendix VD of Part II of the Chinese Pharmacopoeia 2010 Edition), with the unmutated recombinant Saccharomyces cerevisiae (ZL201611254240.X) as a control strain. The results are as follows: Figure 5 When the N at position 442 was mutated to A, S and E residues, the amount of Ala-Gln synthesized was 1.53g, 1.67g and 43g at 5min, and the substrate conversion rate was 70.2%, 76.9% and 66.1% respectively; when it was mutated to P residue, the recombinant yeast completely lost its catalytic activity.
[0101] Application Example 9 Highly Active Yeast Biocatalyst for Ala-Gln Synthesis at High Substrate Concentration
[0102] (1)KP 3.5K A P1800 The reaction mixture was added to a substrate solution containing 8.38 g of AlaOMe (600 mmol / L) and 13.16 g of Gln (900 mmol / L). The reaction temperature was controlled at 28°C, and the reaction pH was maintained at 8.5 with a 6 mmol / L NaOH solution. After the reaction was terminated, the amount of Ala-Gln synthesized was as high as 10.16 g, with a molar conversion of 78%.
[0103] (2)KP 9K A P N442S was added to a substrate solution containing 8.38 g of AlaOMe (600 mmol / L) and 13.16 g of Gln (900 mmol / L). The reaction temperature was controlled at 28°C, and the reaction pH was maintained at 8.5 with 6 mmol / L NaOH solution. After the reaction was terminated, the amount of Ala-Gln synthesized was as high as 10.19 g, with a molar conversion of 78.3%.
[0104] (3)EP 424 A S1800 Add to the substrate solution containing 8.38g AlaOMe (600mmol / L) and 13.16g Gln (900mmol / L). Control the reaction temperature to 24°C, use 6mmol / L NaOH solution to maintain the reaction pH constant at 8.0, and after the reaction is terminated, it is measured that the amount of Ala-Gln synthesis can be as high as 9.77g, with a molar conversion of 75%.
[0105] The high-activity yeast biocatalyst constructed by this method can still maintain stable catalytic performance in the biocatalytic process of high-concentration substrates and has the potential for industrial application.
[0106] (2) S.cerevisiae N442S was added to a substrate solution containing 8.38 g of AlaOMe (600 mmol / L) and 13.16 g of Gln (900 mmol / L). The reaction temperature was controlled to 24°C, and the reaction pH was maintained constant at 8.0 with 6 mmol / L NaOH solution. After the reaction was terminated, it was measured that the amount of Ala-Gln synthesis was as high as 8.44 g, and the molar conversion was 64.8%. Application Example 10 Comparison of the recombinant yeast of the present invention with the strains in the prior art:
[0107] The comparison results of specific data between the present invention and the prior art (patent ZL201611254240.X) for synthesizing Ala-Gln using recombinant yeast are shown in Table 1.
[0108] Table 1
[0109]
[0110] From the results, it can be seen that under similar experimental conditions and bacterial cell usage, the method of the present invention effectively improves the catalytic activity of recombinant yeast. At a substrate concentration of 100 mM, using the same cell amount, KP 3.5K A P1800 and EP 424 A S1800 ,KP 9K N442S and S.cerevisiae N442S increased the yield of alanine glutathione by 20%, 16%, 21.4% and 17% respectively, and the production time was shortened from 40 min to 5 min, and the production intensity was increased by 9.4 times, 11 times, 9.7 times and 8.1 times respectively; the advantage of catalyzing 600 mM substrate was more significant, KP 3.5K A P1800 ,EP 424 A S1800 ,KP 9K Both N442S and S.cerevisiaeN442S can reduce the cell input by 1 / 3, increase the yield of alanine dipeptide by 24%, 21%, 26.6% and 2010.8% respectively, shorten the reaction time to 20 minutes, which is 22.2% of the time consumed by the original patented technology, and increase the production intensity by 10.2 times, 9.8 times, 10.3 times and 8.4 times respectively, laying a good foundation for the large-scale production of Ala-Gln and having huge industrial value.
[0111] Comparative Example 1 Chemical Removal of Glycosylation
[0112] Treatment of recombinant Pichia pastoris KP with deglycosylase 9K A P Secreted AET protein, it was found that the deglycosylated AET enzyme activity was significantly increased ( Figure 4 B). However, the use of deglycosylation enzymes to treat Aet in large-scale production is time-consuming, labor-intensive and uneconomical. In situ deglycosylation of yeast biocatalysts is the inevitable choice to meet the needs of biomanufacturing. In order to improve the activity of yeast biocatalysts, the new strategy proposed in the present invention is to bypass the secretory expression pathway by intracellular expression of Aet and removal of endogenous signal peptides, thereby achieving in situ removal of glycosylation.
[0113] Comparative Example 2N442S mutant expression in E. coli
[0114] The 442 protein asparagine of the coding gene on the recombinant expression vector of the strain used in comparative example 5 in patent document CN111607585A was point mutated to serine, and the mutant vector N442S was obtained, which was transferred into the same expression cell and reacted under its optimal reaction conditions. When the substrate concentration was 100mM, the conversion rate was 80% in 10min, which was not significantly different from that before the mutation. It can be seen that the mutation of this site itself does not show a favorable effect on the catalytic effect of the enzyme.
[0115] The above is only a preferred specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any changes or substitutions that can be easily thought of by a person skilled in the art within the technical scope disclosed in the present invention should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.
Claims
1. A codon-optimized non-glycosylated gene encoding Aet, characterized in that: The gene is a nucleotide sequence that can cause glycosylation process is removed / changed; the removal / change of the nucleotide sequence that can cause glycosylation process includes but is not limited to removal of secretion expression signal peptide, glycosylation site mutation and deglycosylation enzyme treatment; The glycosylation site mutations include N-glycosylation sites and their conserved sequences N67-RT, N318-NS, N442-RT and N608-AT; and O-glycosylation sites T22, T119, S209, T427 and T444.
2. The gene according to claim 1, characterized in that The glycosylation site mutation is N442A or N442E.
3. The recombinant vector encoding the intracellular expression of the Aet gene according to claim 1, characterized in that: The vector is a pPIC series vector or a pRS series vector.
4. The highly active recombinant yeast encoding the intracellular expression of the Aet gene according to claim 1, characterized in that: The recombinant yeast is selected from any one of Saccharomyces cerevisiae, Pichia pastoris, Kluyveromyces lactis and Kluyveromyces marxianus.
5. The method for constructing Aet recombinant yeast encoding intracellular expression of Aet gene according to claim 4, characterized in that: This includes one or a combination of the following methods: (a) Using the method of intracellular expression of Aet to avoid changes in the structure of Aet and improve the catalytic activity of Aet; (b) removing the glycosylation sites to avoid post-modification of Aet and improve the catalytic activity of Aet; (c) The gene sequence without the endogenous signal peptide is used to avoid the change of Aet structure and improve the catalytic activity of Aet.
6. Use of the Aet recombinant yeast constructed according to the method of claim 4 in catalytic production of alanine dipeptide and L-alanyl-L-glutamine, characterized in that: The steps include: (a) dissolving a substrate in a solvent system containing recombinant yeast, wherein the solvent system is selected from any one of water, buffer or cell culture medium; and the substrate is selected from at least one of alanine methyl ester hydrochloride, glutamine and alanine ethyl ester hydrochloride; (b) The reaction pH is controlled at 7.0-10.0 and the reaction temperature is maintained at 18-30°C.
7. The use according to claim 6, characterized in that: The pH range is 7.0-9.
0.
8. The use according to claim 6, characterized in that: The mass concentration of the substrate in the solvent system containing the recombinant yeast is 50-600 mmol / L LaOMe and 50-600 mmol / L Gln.
Citation Information
Cited By
Production method of alpha-amino acid ester acyltransferase and valine dipeptide
CN122038336A
